viewHemoGenyx Pharmaceuticals

Hemogenyx develops new mouse model which could play a big role in future wars

Hemogenyx thinks its new ApbHC mouse model could be used to rapidly develop antibodies to treat deadly pathogens such as Anthrax released as an act of war

ApbHC could also help in the development of new treatments for cancer and autoimmune diseases

HemoGenyx Pharmaceuticals PLC (LON:HEMO) has developed a new generation of humanised mice which it believes could play a vital role in protecting people caught up in biological warfare.

Governments spend billions of dollars every year protecting their citizens from the threat of biological weapons, such as the release of pathogens and toxins including anthrax and smallpox.

READ: Hemogenyx reports encouragin new data for bone marrow transplant therapy

Hemogenyx thinks its new mouse model, called Advanced peripheral blood Hematopoietic Chimera (ApbHC), could potentially be used to help rapidly develop treatments against unknown human-specific pathogens.

ApbHC has “several advantages” over other mouse models, says Hemogenyx, including the absence of Graft versus Host disease – when the mouse rejects the transplanted tissue – which makes the use of certain cells impossible.

Cancer potential

Biodefense is a more extreme application for ApbHC, and Hemogenyx is keen to point out that the new mouse model could also be used to develop new cell therapies for cancer and the conditioning of patients for bone marrow transplantation.

Researchers have also shown that ApbHC can potentially be used for modelling autoimmune diseases such as Lupus, with a goal of developing new treatments for those diseases.

As with its Advanced Hematopoietic Chimeras (AHC), Hemogenyx expects ApbHC will be of “considerable interest” to drug developers, and the initial interest being shown is “promising”.

Boss ‘excited’ by ApbHC

“We are excited by the potential of the ApbHC, a new generation of our humanized mice,” said chief executive Vladislav Sandler.

“The ApbHC has allowed us to rapidly obtain in vivo data on the efficacy of our CDX antibodies against AML.

“We are actively developing and expanding the potential use of the ApbHC for disease modelling, the development of new therapeutics, and biodefense applications.

“Our ApbHC has also generated significant interest from third parties who also see its potential for disease modelling and drug development.”

Shares jumped 7.5% to 3.22p in early deals on Monday.

Quick facts: HemoGenyx Pharmaceuticals

Price: 7.8 GBX

Market: LSE
Market Cap: £33.82 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the...



HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18

2 min read